Colorcon expands coating portfolio with DuPont’s Aquacoat

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/Sasha Brazhnik)
(Image: Getty/Sasha Brazhnik)

Related tags: Colorcon, Dow chemical company, DuPont, Aquacoat

Colorcon adds DuPont’s Aquacoat technology, held in CR Alliance’s portfolio, whilst planning to transition existing customers over to the company.

DuPont Nutrition & Biosciences, a biotech business unit of DowDuPont Specialty Products Division, has agreed to extend the Controlled Release (CR) Alliance with Colorcon by adding the Aquacoat range of modified release products.

Aquacoat is a technology DuPont acquired from FMC​. The product line includes Aquacoat ECD, a colloidal dispersion of ethylcellulose polymer for sustained release, and Aquacoat CPD, for enteric coating applications.

The primary release mechanism is drug diffusion across a water-insoluble membrane. As stated by Colorcon, the Aquacoat ECD "offers stable, reproducible, pH-independent release profiles." ​The coatings are designed for use in both pharmaceutical and nutritional solid dose applications.

Addition of plasticizer is required for use, with the type and level of addition based on the permeability and the drug release profile required.

The nature of Colorcon’s agreement to add Aquacoat to the CR Alliance could not be disclosed.

A long-term collaboration

Colorcon and DuPont entered CR Alliance, a controlled release collaboration in 2007​, according to which Colorcon would be responsible for the development and distribution of DuPont’s pharmaceutical products for use in oral controlled release applications.

A spokesperson from Colorcon told us that the company’s current goal is to “transition existing customers over to Colorcon, who from May 1st will be serviced through Colorcon directly and will benefit from Colorcon’s technical knowledge and applications expertise in functional film coating systems and excipients.”

Related news

Show more

Related products

show more

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Related suppliers

Follow us

Products

View more